Management of extensively drug-resistant Acinetobacter baumannii bacteremia with cefiderocol and sulbactam-durlobactam: a case report.

BACKGROUND

Extensively drug-resistant (XDR) Acinetobacter baumannii presents an urgent threat to public health due to its significant morbidity and mortality, with limited evidence-based treatment options. Recent drug developments of cefiderocol (FDC) and sulbactam-durlobactam (SUD) provide novel treatment options for XDR A. baumannii.

CASE SUMMARY: We present the case of a patient with XDR A. baumannii bacteremia following a prolonged hospital course for gangrenous cholecystitis and hospital-acquired bacterial pneumonia. He completed a 14-day course of FDC and SUD with clinical resolution and was discharged home.

CONCLUSION

This case demonstrates the potential efficacy of FDC combined with SUD in treating XDR A. baumannii bacteremia, highlighting the need for further research into combination therapy regimens for XDR A. baumannii.